Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Reviews/Commentaries/ADA Statements

Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome

A systematic review and meta-analysis

  1. Rita S. Suri, MD1,
  2. William F. Clark, MD1,
  3. Nick Barrowman, PHD2,
  4. Jeffrey L. Mahon, MD, MSC34,
  5. Heather R. Thiessen-Philbrook, MMATH1,
  6. M. Patricia Rosas-Arellano, MD, PHD1,
  7. Kelly Zarnke, MD, MSC35,
  8. Jocelyn S. Garland, MD6 and
  9. Amit X. Garg, MD, MA, PHD13
  1. 1Division of Nephrology, London Health Sciences Center, University of Western Ontario, London, Canada
  2. 2Chalmers Research Group, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada
  3. 3Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada
  4. 4Division of Endocrinology, London Health Sciences Center, University of Western Ontario, London, Canada
  5. 5Department of Medicine, London Health Sciences Center, University of Western Ontario, London, Canada
  6. 6Division of Nephrology, Kingston General Hospital, Queen’s University, Kingston, Canada
  1. Address correspondence and reprint requests to Rita Suri, MD, FRCPC, FACP, Kidney Clinical Research Unit, London Health Sciences Center, Room ELL-111 Victoria Hospital, 800 Commissioners Rd. East, London, Ontario, Canada N6A 4G5. E-mail: rita.suri{at}lhsc.on.ca
Diabetes Care 2005 Oct; 28(10): 2556-2562. https://doi.org/10.2337/diacare.28.10.2556
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

A systematic review and meta-analysis

Abstract

OBJECTIVE—To quantify the incidence of diabetes during the acute phase of diarrhea-associated hemolytic uremic syndrome (D+HUS) and to identify features associated with its development.

RESEARCH DESIGN AND METHODS—A systematic review and meta-analysis of articles assessing diabetes during D+HUS was conducted. Relevant citations were identified from Medline, Embase, and Institute for Scientific Information Citation Index databases. Bibliographies of relevant articles were hand searched. All articles were independently reviewed for inclusion and data abstraction by two authors.

RESULTS—Twenty-one studies from six countries were included. Only 2 studies reported a standard definition of diabetes; 14 defined diabetes as hyperglycemia requiring insulin. The incidence of diabetes during the acute phase of D+HUS could be quantified in a subset of 1,139 children from 13 studies (1966–1998, age 0.2–16 years) and ranged from 0 to 15%, with a pooled incidence of 3.2% (95% CI 1.3–5.1, random-effects model, significant heterogeneity among studies, P = 0.007). Children who developed diabetes were more likely to have severe disease (e.g., presence of coma or seizures, need for dialysis) and had higher mortality than those without diabetes. Twenty-three percent of those who developed diabetes acutely died, and 38% of survivors required long-term insulin (median follow-up 12 months). Recurrence of diabetes was possible up to 60 months after initial recovery.

CONCLUSIONS—Children with D+HUS should be observed for diabetes during their acute illness. Consideration should be given to long-term screening of D+HUS survivors for diabetes.

  • D+HUS, diarrhea-associated hemolytic uremic syndrome
  • HUS, hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is characterized by acute hemolytic anemia, thrombocytopenia, and renal failure (1). The incidence of HUS is estimated at 1 per 50,000 person-years for children <18 years of age (2). Over 90% of childhood cases are associated with diarrhea and gastroenteritis due to Shiga toxin–producing Escherichia coli O157:H7 (3). Also known as “typical” or “primary” HUS, diarrhea-associated HUS (D+HUS) causes toxin-mediated endothelial cell damage, resulting in thrombotic microangiopathy and intraluminal thrombosis of small vessels, with subsequent tissue ischemia and necrosis (4). Although renal and central nervous system involvement predominate, the pancreas can be affected, causing acute diabetes. Autopsy studies have demonstrated thrombosis of vessels supplying the islets of Langerhans with preservation of the exocrine pancreas (5,6). Although renal complications of HUS have received much attention (7), little is known about the incidence and management of diabetes during D+HUS. Using techniques described by Stroup et al. (8), this systematic review was conducted to better understand diabetes associated with D+HUS.

RESEARCH DESIGN AND METHODS

Research questions

The primary research questions were as follows. 1) What is the incidence of diabetes during acute D+HUS? 2) Is diabetes during acute D+HUS associated with more severe D+HUS, as defined by the presence of coma or seizures, requirement for dialysis, or death? and 3) What is the long-term prognosis of those who develop diabetes during acute D+HUS? Specifically, what proportion of children recover, have permanent diabetes, and relapse after initial recovery?

Finding relevant studies

All language case series, cohort studies, and randomized trials that described patients with D+HUS (idiopathic, diarrhea, or E. coli O157:H7 associated) and examined patients for hyperglycemia or diabetes were included. Two reviewers independently evaluated eligibility of all studies. A third reviewer resolved disagreements.

Citations were retrieved from Medline, Embase, and the Institute for Scientific Information from 1966 to 28 February 2005. The search strategy was pilot tested and modified with known relevant articles in an iterative process and included the terms hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, diabetes mellitus, glucose intolerance, hyperglycemia, glucose, insulin, pancreas, pancreatic diseases, pancreatic necrosis, extrarenal, and nonrenal. Reference lists of included articles were hand searched, and articles citing included articles in the Institute for Scientific Information index were reviewed.

Data abstraction

To summarize the characteristics of the included studies, two investigators developed a methodological assessment tool based on criteria of internal and external validity, as previously described for studies of prognosis (9) (Table 1). Using standardized forms, two investigators independently rated each article on these criteria, as well as abstracted data on study, patient, and outcome characteristics. Disagreements were resolved by consensus.

Statistical analysis

The mean age, proportion of patients with various characteristics, and long-term outcomes are described for all children with diabetes and D+HUS. CIs for single proportions were obtained using the Wilson score method (10).

Those studies that described incidence of diabetes were included in the meta-analysis. Data from these studies are presented in tabular form. χ2 Tests were used to assess between-study heterogeneity. The I2 statistic, which describes the percentage of total variation across studies due to heterogeneity rather than chance, was calculated (11). Due to significant heterogeneity among studies, an approach based on generalized estimating equations, which accounted for within- and between-study variability (random-effects modeling), was used to derive pooled estimates and their variances (12). Overall, each study contributed a weight of between 3.7 and 11.7%. Estimates were computed using R2.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

For studies included in the meta-analysis, the odds of having diabetes with severe D+HUS (i.e., central nervous system symptoms, need for dialysis) was compared with the odds of having diabetes without severe D+HUS; the odds of dying with diabetes was compared with the odds of dying without diabetes. As between-study heterogeneity was not significant for the individual odds ratios (ORs), the Mantel-Haenszel method was used to calculate fixed-effects pooled ORs for each of these three factors (13). All analyses were performed with complete data, and P values <0.05 were considered statistically significant.

RESULTS

Finding and selecting studies

Three hundred eighty-four citations in six languages were screened from all sources, and 93 full-text articles were retrieved for detailed review. Twenty-one articles met inclusion criteria (5,14–33). Seven articles seemed to describe patients already included in this review (34–40). Any additional data from these studies were combined with included studies. The agreement beyond chance between two independent reviewers for article inclusion was good (κ = 0.74).

Methodological assessment of included articles

Interrater reliability in the assessment of methodological criteria was good (overall κ = 0.65 [range 0.39–1.0]) (Table 1). No study met all criteria. Cohort studies met 3–11 of 15 criteria, while case series met 3–9 of 11 criteria.

Definition of diabetes

Patients were classified as having diabetes based on the primary author’s assessment or if it was evident that the patient was treated with insulin. In one study (23), it was unclear whether the patients were treated with insulin, as the article just stated diabetes was present. Three stated “insulin-dependent diabetes” was present (5,21,26), and one stated “diabetic ketoacidosis” was present (22). Of the remaining 16 studies, 15 referred to patients with hyperglycemia with or without ketoacidosis treated with insulin (14–20,24,27–33); the glucose cut points defining hyperglycemia were specified in only one study (glucose >360 mg/dl [20 mmol/l] on 3 consecutive days) (24). One study defined diabetes according to standard international criteria (25).

Meta-analysis of diabetes incidence with D+HUS

Point estimates of the incidence of diabetes with D+HUS were reported in 13 of 21 studies (14–26); these were pooled using meta-analysis (Table 2). These 13 studies described 1,189 children aged 0.2–16 years, from five different countries, over the period 1966–1998. There were no adult studies meeting inclusion criteria. One study described an outbreak of D+HUS from meat contaminated with Shiga toxin–producing E. coli (17), 10 of 13 studies described sporadic D+HUS (14–16,18,19,21–25), and 2 studies described both outbreak and sporadic D+HUS (20,26). Follow-up was restricted to the acute phase of D+HUS (<3 months) in 6 of 13 studies (14–16,19,24,25) and to 12–48 months in 7 of 13 studies (17,18,20–23,26).

The incidence of diabetes in the individual studies ranged from 0 to 15% (Fig. 1). The variability among studies was larger than would be expected by chance (significant heterogeneity, P = 0.007), with I2 = 61%. Given the high between-study variability, the results pooled using the random-effects model should be interpreted with caution. The pooled estimate of diabetes was 3.2% (random-effects model, 95% CI 1.3–5.1%). We recalculated the pooled estimates after excluding studies that were outliers or qualitatively different. The pooled estimates were similar when studies that did not define diabetes (23) or had some patients with secondary HUS (21,22,24) were excluded (3.4% [95% CI 1.4–5.5] and 3.9% [1.5–6.2], respectively). Two small studies (14,17) had the highest point estimates (8.1 and 15%); the pooled estimate was 2.3% (1.1–3.4) when these two studies were excluded.

Disease severity and diabetes during acute D+HUS

The presence of diabetes was associated with more severe disease. Patients with central nervous system symptoms were more likely to develop diabetes than those without (OR 12.0 [95% CI 4.2–34.2], P < 0.00001, n = 471 patients in seven studies), as were patients who required acute dialysis versus those who did not (5.4 [1.6–18.4], P = 0.008, n = 355 patients in five studies). Patients with diabetes were also more likely to die than those without diabetes (15.0 [5.8–38.9], P < 0.00001, n = 712 patients in eight studies).

Features and long-term prognosis of children who develop diabetes with D+HUS

The 21 included studies described 49 children who developed diabetes during acute D+HUS (Table 3). All children except one developed diabetes within 14 days of presentation to hospital (mean 8 days [range 1–60]). Insulin was used in 86% of patients (n = 44), and ketoacidosis developed in 64% (n = 11). In at least one patient, hyperglycemia was noted before the initiation of peritoneal dialysis (18). Pancreatic autoantibodies, including islet cell, insulin, GAD, and insulinoma-associated protein 2 antibodies, were measured in five patients and found to be negative in all; methods used to measure these antibodies were not described (14,29–31,33). These five patients, as well as two additional subjects, were reported to have some measure of impaired insulin secretion (low endogenous insulin levels [14,25,28,31], low basal C-peptide levels [29], impaired response to Sustacal challenge [30], or abnormal first-phase insulin response to intravenous glucose [33]).

Long-term outcome was reported for 44 of 49 children. Of these 44, 23% died acutely (95% CI 13–37). In the 34 survivors, the mean follow-up was 32 months (range 0–180). Thirty-eight percent (95% CI 24–55) of survivors were left with persistent diabetes requiring insulin; 11 of 34 had persistent diabetes from the outset, while 2 of 34 redeveloped diabetes 3 and 60 months after initial apparent recovery. The remaining 21 children (62% [95% CI 45–76]) were reported to have complete recovery from diabetes, having required insulin for 19–120 days. However, follow-up was <12 months or not reported for 48% of these children.

CONCLUSIONS

Based on the available evidence, the incidence of diabetes (hyperglycemia requiring insulin) during acute D+HUS in children <16 years of age ranged from 0 to 15%, with pooled incidence estimated at 3.2% (95% CI 1.3–5.1). This is in contrast to the reported general population incidence of childhood type 1 diabetes of 0.013–0.040% (41–43). The development of diabetes was associated with severe disease, marked by central nervous system symptoms, the need for acute dialysis, and mortality. However, whether diabetes develops in the setting of milder disease is unknown, as all patients were not tested.

These findings would suggest frequent monitoring of blood glucose during acute D+HUS, especially for patients on peritoneal dialysis with glucose solutions. Early aggressive treatment of hyperglycemia will not only prevent ketoacidosis but may improve acute outcomes, as has been shown in other critically ill patients (44,45).

Potential pathophysiology of diabetes during acute D+HUS

The pathophysiology of hyperglycemia during D+HUS is not known. Some have proposed that it is related to the initiation of peritoneal dialysis with glucose solutions or to the use of medications such as glucocorticoids or diazoxide. This is unlikely, as the hyperglycemic effects of diazoxide are transient (46); some patients never received glucocorticoids (18,19,25,26,28,30,31), diazoxide (18,19,25,26,29–31,33), or peritoneal dialysis (20,30); and one patient developed diabetes before peritoneal dialysis was instituted (18). It is possible that the children may have had “stress hyperglycemia” rather than true diabetes (47). However, stress hyperglycemia is usually transient (48), while here 38% of survivors required insulin at 12 months. Rather, the hyperglycemia may be due to insulin deficiency, as suggested by impaired insulin secretion in all eight patients who were tested (14,25,28–31,33).

The mechanism of insulin deficiency does not appear to be immune, as pancreatic autoantibodies were negative in all five patients studied (14,29–31,33). A viral etiology producing both diabetes and D+HUS is also unlikely, as viral studies were negative in one patient (31), viral particles were absent at autopsy in two patients (27,28), and the pathogenesis of D+HUS is not viral but related to Shiga toxin–producing bacteria (3). Given that absolute insulin deficiency is not silent, it is unlikely that diabetes predated D+HUS in all patients. The mechanism may instead be the direct result of HUS with thrombotic microangiopathy of the pancreatic microvasculature. Pancreatic necrosis was present in four of five children with diabetes who had autopsies (25,27,28); two of these children demonstrated extensive thrombosis of pancreatic arterides (25,28). That several patients had concomitant exocrine pancreatic dysfunction also suggests a vascular mechanism.

The reasons for predilection of the pancreas to toxin-mediated damage are unclear. Gb3 receptors, associated with toxin binding in the kidney (49), do exist in the pancreas, although not in high density (50). During acute D+HUS, these receptors may be upregulated, and islet cells may be more susceptible to hypoxic ischemic injury due to decreased ability to clear free radicals (51). There are likely other factors involved in the pathophysiology, as one patient with diabetes was described as having no detectable pancreatic injury at autopsy (14).

Long-term outcomes

Of children who developed diabetes during D+HUS and survived, over one-third had permanent diabetes requiring insulin 6 months to 15 years after the acute phase, whereas approximately two-thirds were reported to recover. Given that relapse can occur up to 5 years after the acute illness (32) and that almost 50% of recovering children were not followed for >1 year, the rate of permanent diabetes may in fact be higher than reported.

The mechanism of relapse may be continued loss of islet cells, or alternatively, decreased islet reserve in the face of a predisposition to type 2 diabetes. If this is the case, then even those who were not identified to have hyperglycemia during the acute phase of D+HUS may be at long-term risk of diabetes due to subclinical islet cell injury. Further studies are needed to determine the long-term risk of diabetes in survivors of D+HUS. Until then, consideration should be given to screening all survivors of D+HUS for diabetes with an oral glucose tolerance test at least 1 and 2 years’ postillness.

Limitations of this review

The quality of a review is dependent on the quality of the original studies. Although all included studies used a cohort representative of patients with D+HUS at their institutions, the majority were retrospective, few reported a specific definition for D+HUS or diabetes, and long-term follow-up was variable. We only included articles mentioning diabetes, predisposing to potential selection of positive studies and overestimation of the true incidence. To ascertain the impact of such a publication bias, we determined that at least 90 studies, with 50 patients per study, would have to report no cases of diabetes in order to change the pooled incidence from 3.2 to <0.5%. Alternatively, this review may have underestimated the true incidence of diabetes, given that diabetes was not systematically assessed in any of the 13 studies.

Finally, it could be argued that a meta-analysis should not have been performed due to the substantial heterogeneity among studies, potentially resulting in an erroneous estimate of the true incidence of diabetes with D+HUS. The random-effects pooled estimate represents an approximation of the mean incidence, accounting for the variable precisions of the individual estimates of incidence and their pattern of variation. The precision of the pooled estimate takes into account the uncertainty in the estimates from the included studies, as well as the additional between-study variation observed. In keeping with this point, the pooled estimates calculated after excluding outliers fell within the 95% CI of the pooled estimate calculated using all included studies. Thus, the overall pooled estimate with 95% CIs allows us to succinctly summarize existing evidence. Ideally, we would have liked to perform metaregression to explore reasons for heterogeneity but were limited by inadequate statistical power. Potential reasons for the variability include differences in surveillance for diabetes (given that none of the included studies’ main purpose was to evaluate incidence of diabetes) and differing severity of D+HUS.

Despite its limitations, this review summarizes the best available evidence on the important but infrequently recognized complication of diabetes associated with D+HUS and highlights the need for further research.

Diabetes is an important complication of D+HUS. Early identification and aggressive treatment of hyperglycemia during D+HUS may improve outcomes acutely. Future studies that prospectively evaluate the incidence of this complication both during the acute phase of D+HUS and after long-term follow-up are needed. Meanwhile, children who present with D+HUS should have aggressive surveillance and treatment of hyperglycemia. Consideration should also be given to long-term screening of all survivors of D+HUS for diabetes.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Incidence of diabetes (DM) during acute D+HUS in 13 cohort studies. Point estimates for each study are presented with 95% CIs. The size of each square is proportional to the number of patients in each study. The random-effects pooled estimate was 3.2% (95% CI 1.3–5.1) (see text).

View this table:
  • View inline
  • View popup
Table 1—

Methodological assessment of included articles

View this table:
  • View inline
  • View popup
Table 2—

Summary of cohort studies* reporting diabetes during acute D+HUS, 1966 to present

View this table:
  • View inline
  • View popup
Table 3—

Characteristics of 49 children with diabetes during acute D+HUS reported in the literature, 1966 to present

Acknowledgments

This work was supported by the Canadian Diabetes Association and the Ontario Ministry of Health.

This study was performed in conjunction with the Walkerton Health Study. Other study investigators include Douglas Matsell, MD, Louise Moist, MD, MSc, and Marina Salvadori, MD.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

  • DIABETES CARE

References

  1. ↵
    Gasser C, Gautier E, Steck A, Seibenmann RE, Oechslin R: [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr 85: 905–909, 1955 [article in German]
    OpenUrlPubMed
  2. ↵
    Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT: The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 323:1161–1167, 1990
    OpenUrlPubMedWeb of Science
  3. ↵
    Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H: The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775–782, 1985
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Proulx F, Seidman EG, Karpman D: Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 50:163–171, 2001
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Gallo EG, Gianantonio CA: Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol 9:117–119, 1995
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo GE, Sojo ET: The hemolytic-uremic syndrome. Nephron 11:174–192, 1973
    OpenUrlPubMedWeb of Science
  7. ↵
    Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF: Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370, 2003
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012, 2000
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Randolph A, Bucher H, Richardson WS, Wells G, Tugwell P, Guyatt G: Prognosis. In User’s Guide to the Medical Literature. Guyatt G, Rennie D, Eds. Chicago, American Medical Association, 2002, p. 141–154
  10. ↵
    Newcombe RG: Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857–872, 1998
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Higgins JPT, Thompson JG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analysis. BMJ 327:557–560, 2003
    OpenUrlFREE Full Text
  12. ↵
    Zhou XH, Brizendine EJ, Pritz MB: Methods for combining rates from several studies. Stat Med 18:557–566, 1999
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748, 1959
  14. ↵
    Andreoli SP, Bergstein JM: Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr 100:541–545, 1982
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Bernard A, Tounian P, Leroy B, Bensman A, Girardet JP, Fontaine JL: [Digestive manifestations in hemolytic uremic syndrome in children]. Arch Pediatr 3:533–540, 1996 [article in French]
    OpenUrlCrossRefPubMed
  16. ↵
    Brandt J, Wong C, Mihm S, Roberts J, Smith J, Brewer E, Thiagarajan R, Warady B: Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 110:371–376, 2002
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED: Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519–526, 1994
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Crawford BA, Roy LP, Knight JF: Hyperglycaemia complicating haemolytic uraemic syndrome. J Paediatr Child Health 26:225–226, 1990
    OpenUrlCrossRefPubMed
  19. ↵
    de la Hunt MN, Morris KP, Coulthard MG, Rangecroft L: Oesophageal and severe gut involvement in the haemolytic uraemic syndrome. Br J Surg 78:1469–1472, 1991
    OpenUrlCrossRefPubMed
  20. ↵
    Elliott EJ, Robins-Browne RM, O’Loughlin EV, Bennett-Wood V, Bourke J, Henning P, Hogg GG, Knight J, Powell H, Redmond D, Contributors to the Australian Paediatric Surveillance Unit: Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 85:125–131, 2001
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Guyot C, Daniel MD, Roze JC, Renoult E, Dubigeon P, Buzelin F: [Prognosis of hemolytic uremic syndrome in children. Importance of extrarenal involvement]. Arch Fr Pediatr 43:253–258, 1986 [article in French]
    OpenUrlPubMedWeb of Science
  22. ↵
    Hughes DA, Beattie TJ, Murphy AV: Haemolytic uraemic syndrome: 17 years’ experience in a Scottish paediatric renal unit. Scott Med J 36:9–12, 1991
    OpenUrlPubMedWeb of Science
  23. ↵
    Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H: Haemolytic uraemic syndromes in the British Isles 1985–8: association with verocytotoxin producing Escherichia coli. Part 1: clinical and epidemiological aspects. Arch Dis Child 65:716–721, 1990
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Robitaille P, Gonthier M, Grignon A, Russo P: Pancreatic injury in the hemolytic-uremic syndrome. Pediatr Nephrol 11:631–632, 1997
    OpenUrlCrossRefPubMed
  25. ↵
    Robson WL, Leung AK, Brant R, Trevenen CL, Stephure DK: Hyperglycemia in diarrhea-associated hemolytic-uremic syndrome. Nephron 71:54–58, 1995
    OpenUrlCrossRefPubMed
  26. ↵
    Taylor CM, White RH, Winterborn MH, Rowe B: Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands. Br Med J (Clin Res Ed) 292:1513–1516, 1986
  27. ↵
    Burns JC, Berman ER, Fagre JL, Shikes RH, Lum GM: Pancreatic islet cell necrosis: association with hemolytic-uremic syndrome. J Pediatr 100:582–584, 1982
    OpenUrlCrossRefPubMed
  28. ↵
    Primhak RA, Taitz LS, Variend S, Webb DH, Cser A: Necrosis of the pancreas in the haemolytic uraemic syndrome. J Clin Pathol 37:655–658, 1984
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Zeidan SF, Coulthard MG: Transient glucose intolerance associated with the haemolytic-uraemic syndrome. Pediatr Nephrol 1:605–607, 1987
    OpenUrlCrossRefPubMed
  30. ↵
    Pena DR, Vaccarello M, Neiberger RE: Severe hemolytic uremic syndrome associated with rhabdomyolysis and insu-lin-dependent diabetes mellitus. Child Nephrol Urol 11:223–227, 1991
    OpenUrlPubMed
  31. ↵
    al Herbish AS, al Rasheed SA: Persistent insulin-dependent diabetes mellitus in hemolytic uremic syndrome. Child Nephrol Urol 12:59–61, 1992
    OpenUrlPubMed
  32. ↵
    Bendel-Stenzel MR, Kashtan CE, Sutherland DE, Chavers BM: Simultaneous pancreas-kidney transplant in two children with hemolytic-uremic syndrome. Pediatr Nephrol 11:485–487, 1997
    OpenUrlCrossRefPubMed
  33. ↵
    Kordonouri O, Velin P, Hasala M, Lennert T, Danne T: Beta-cell dysfunction complicating haemolytic uraemic syndrome. Nephrol Dial Transplant 13:1271–1272, 1998
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Andreoli S, Bergstein J: Exocrine and endocrine pancreatic insufficiency and calcinosis after hemolytic uremic syndrome (Letter). J Pediatr 110:816–817, 1987
    OpenUrlPubMed
  35. ↵
    Grodinsky S, Telmesani A, Robson WL, Fick G, Scott RB: Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis. J Pediatr Gastroenterol Nutr 11:518–524, 1990
    OpenUrlPubMedWeb of Science
  36. Robson LM, Leung AK: Hyperglycaemia in children with haemolytic uraemic syndrome (Letter). J Paediatr Child Health 27:64–65, 1991
    OpenUrlCrossRef
  37. ↵
    Robson WL, Leung AK, Trevenen CL, Brant R: Diarrhea-associated hemolytic uremic syndrome. Can Fam Physician 39:2139–2145, 1993
    OpenUrlPubMed
  38. ↵
    Tapper D, Tarr P, Avner E, Brandt J, Waldhausen J: Lessons learned in the management of hemolytic uremic syndrome in children. J Pediatr Surg 30:158–163, 1995
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Henning PH, Tham EB, Martin AA, Beare TH, Jureidini KF: Haemolytic-uraemic syndrome outbreak caused by Escherichia coli O111:H-: clinical outcomes. Med J Aust 168:552–555, 1998
    OpenUrlPubMedWeb of Science
  40. ↵
    Brandt JR, Joseph MW, Fouser LS, Tarr PI, Zelikovic I, McDonald RA, Avner ED, McAfee NG, Watkins SL: Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Nephrol 12:222–225, 1998
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Patterson CC, Dahlquist G, Soltesz G, Green A: Is childhood-onset type I diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 44(Suppl. 3):B9–B16, 2001
    OpenUrl
  42. Lipman TH, Chang Y, Murphy KM: The epidemiology of type 1 diabetes in children in Philadelphia 1990–1994: evidence of an epidemic. Diabetes Care 25:1969–1975, 2002
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Newhook LA, Curtis J, Hagerty D, Grant M, Paterson AD, Crummel C, Bridger T, Parfrey P: High incidence of childhood type 1 diabetes in the Avalon Peninsula, Newfoundland, Canada. Diabetes Care 27:885–888, 2004
    OpenUrlAbstract/FREE Full Text
  44. ↵
    van den BG, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367, 2001
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515, 1997
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Danforth E Jr: Hyperglycemia after diazoxide. N Engl J Med 285:1487, 1971
    OpenUrl
  47. ↵
    Valerio G, Franzese A, Carlin E, Pecile P, Perini R, Tenore A: High prevalence of stress hyperglycaemia in children with febrile seizures and traumatic injuries. Acta Paediatr 90:618–622, 2001
    OpenUrlPubMedWeb of Science
  48. ↵
    Shehadeh N, On A, Kessel I, Perlman R, Even L, Naveh T, Soloveichik L, Etzioni A: Stress hyperglycemia and the risk for the development of type 1 diabetes. J Pediatr Endocrinol Metab 10:283–286, 1997
    OpenUrlPubMed
  49. ↵
    Boyd B, Lingwood C: Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207–210, 1989
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    Ohyama C, Orikasa S, Kawamura S, Satoh M, Suzuki K, Saito S, Fukushi Y, Yoshikawa K, Hoshi S: [Immunohistochemical study of globotriaosyl ceramide (Gb3) in testicular tumors]. Nippon Hinyokika Gakkai Zasshi 84:1308–1315, 1993 [article in Japanese]
    OpenUrlPubMed
  51. ↵
    Oberley LW: Free radicals and diabetes. Free Radic Biol Med 5:113–124, 1988
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 28 (10)

In this Issue

October 2005, 28(10)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome
Rita S. Suri, William F. Clark, Nick Barrowman, Jeffrey L. Mahon, Heather R. Thiessen-Philbrook, M. Patricia Rosas-Arellano, Kelly Zarnke, Jocelyn S. Garland, Amit X. Garg
Diabetes Care Oct 2005, 28 (10) 2556-2562; DOI: 10.2337/diacare.28.10.2556

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome
Rita S. Suri, William F. Clark, Nick Barrowman, Jeffrey L. Mahon, Heather R. Thiessen-Philbrook, M. Patricia Rosas-Arellano, Kelly Zarnke, Jocelyn S. Garland, Amit X. Garg
Diabetes Care Oct 2005, 28 (10) 2556-2562; DOI: 10.2337/diacare.28.10.2556
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic Syndrome and Risk of Cancer
  • Emerging Applications of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine
  • Diabetes and Risk of Parkinson’s Disease
Show more Reviews/Commentaries/ADA Statements

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.